Aromatase inhibitors are the gold standard in the treatment of hormone receptor-positive breast cancer, but lead to an arthralgia syndrome which is implicated in 13-22% of noncompliance. This is the first systematic review of the efficacy of existing management strategies for this side effect.
INTRODUCTION
Aromatase inhibitors (AIs) are the gold-standard treatment for hormone-receptor positive breast cancer in postmenopausal women and are superior to tamoxifen in terms of relapse-free survival. 1 However, these drugs lead to a syndrome of arthralgia and musculoskeletal symptoms, which has been characterized in several reviews. [2] [3] [4] The incidence of this syndrome in trials has been reported to be up to 36 .5% in women taking AIs, while in the community, the rate has been reported to be as high as 80%. 2 Aromatase inhibitor-induced musculoskeletal symptom (AIMSS) typically affects the wrists, hands and knees, 3 and can be severe enough to cause AI noncompliance.
It is implicated in 13-22% of discontinuations of AI therapy at 12-month follow-up. 3 The etiology is unclear, although estrogen depletion may be responsible. 3 Despite the evident importance of treating this syndrome, clinicians are still unclear as to its optimal management.
A wealth of primary studies have been conducted in the last decade, but there are as yet no systematic reviews of the evidence. The most recent major reviews into the management of AIMSS have been done by Lombard et al., 2 Niravath 3 and Gaillard and Stearns. 4 Management strategies supported by at least one trial in these reviews are acupuncture, vitamin D, exercise, yoga, switch from one AI to another, diuretics, duloxetine, Chinese herbal remedies and glucosamine. However, these studies do not contain a systematic search strategy to find the primary studies and no formal appraisal of their validity. The largest review contains only 10 trials. 2 Several researchers have attempted to create an algorithm to guide the management of AIMSS. 3, [5] [6] [7] [8] [9] However, most are based either primarily or entirely on anecdotal evidence and evidence borrowed from other fields of research such as arthritis, rather than trials specific to AIMSS. Even Niravath's study, the largest, is based only on seven trials, only one of which is a randomised controlled trial (RCT). 3 Some interventions included in the algorithms are supported only by a single pilot trial. Interestingly, many of these algorithms emphasize the use of acetaminophen, non-steroidal anti-inflammatory drugs and other pharmacological analgesics, despite the fact none of them cite any trial evidence to support their use in AIMSS. They have only been informally reported to be beneficial in cross-sectional surveys. 2, 10 It is also likely that many new trials have been undertaken that are not covered by any of the existing reviews, justifying a new appraisal of the current evidence. Hence, this study aims to be a thorough and up-to-date systematic review, focusing on the main interventions in the literature. By summarizing and evaluating the evidence for the management of AIMSS, it aims to clarify the desirable goals and methods of future research.
F I G U R E 1 Flow diagram

METHODS
The systematic review was planned, conducted and reported according to the PRISMA statement. 11
Search and inclusion process
This study included trials of interventions for the management of Of these, only completed studies in full text form, representing the most recent findings if part of a sequence of trials by the same authors, were selected for analysis. Trials available only in abstract form were not analyzed but were listed for reference.
Study selection
The initial search yielded 1986 articles. Articles unrelated to AIMSS, and duplicate articles, were excluded by title. Of the resultant 354 articles, only studies about the management of AIMSS were carried forward; the rest were sorted into background categories.
Of the 101 management studies, 81 were trials of individual interventions. The remaining 20 were reviews and were searched for further references to specific interventions, but none were found. The 81 trials were reduced to 55 by removing feasibility and pilot trials where a more recent version was available. After reading the abstracts, 30 were found to be complete and relevant and were included in the review, of which 21 were full texts and nine were available only in abstract form.
Data collection and analysis
The following key parameters were extracted into and conclusion/discussion points. Each study was evaluated using the Cochrane Collaboration Tool for assessing risk of bias. 12 For each study, the various domains were individually designated as low, unclear or high risk of bias according to the tool's scoring guidelines. Table 1 summarizes the results of the risk of bias analysis that uses a "traffic light" color system where green is low, yellow is unclear and red is high risk of bias. Although a validated tool was used for the risk of bias assessment, there are some ambiguities in how it was applied.
Summary measures and synthesis
The tool does not specifically indicate what level of incomplete outcome completion constitutes a high, unclear or low risk of bias, so we designated a 10-15% rate as high depending on the sample size. Furthermore, instead of "other risk of bias," we have focused on the measurement and level of compliance, as this was highly variable between trials. In the outcome reporting column, those trials labeled "unclear risk of bias" were deemed so in line with the Cochrane criteria because we could not find a corresponding registered protocol.
Due to the heterogeneity of the interventions and outcomes, a meta-analysis was not completed. Instead, the results for each intervention group are summarized in Table 2 comparing the methods, size, outcome measures and conclusions of each study. Tables 1 and 2 show the risk of bias assessment and the summary of study characteristics and results, respectively. 
RESULTS
TA B L E 1 Risk of bias assessment
Vitamin D
Given that estrogen is required in the activation of vitamin D and that vitamin D may be pertinent to fracture risk and joint tissue health, 13 it has been postulated that an AI-induced vitamin D deficiency may contribute to the mechanism for AIMSS. Furthermore, a large proportion of women with breast cancer have vitamin D insufficiency or deficiency despite standard supplementation. 14 The results from the trials in this review were mostly in favor of vitamin D, but there are several qualifying issues. The Khan et al. 15 and Prieto-Alhmabra et al. 16 
Switch to another AI
While not strictly an intervention, switching from one AI to another with potentially milder side effects may enable longer term adherence to AIs. AIMSS appears to be a class effect shared among all AIs, 3 but anastrozole, letrozole and exemestane are also similar in efficacy, 4 making a switch between drugs an option worth investigating.
Briot et al.'s study, 18 the one study in this group, was a singlearm prospective trial of 179 people. After a 1-month washout period, patients who had discontinued anastrozole due to AIMSS were given a different AI, letrozole, for 6 months. Improvement in AIMSS and in extended compliance to AI medication beyond 6 months was documented. However, there was no control. The trial examined only anastrozole and letrozole, in that order, and future studies may explore other "switch" combinations.
Yoga
Yoga, with its combined mental and physical approach to symptom relief, is popular among women with breast cancer, 19 and several studies suggest a beneficial effect on joint pain in this population. 20, 21 The three studies in this category were overwhelmingly in favor of yoga, but have numerous weaknesses. The Galantino et al.'s trials 22, 23 were quantitative and qualitative analyses, respectively, of the same feasibility study data, consisting of only 10 people. 
Exercise
Exercise has been shown to help with osteoarthritis, 24, 25 leading to its consideration in AIMSS. It is especially appealing as a 2012 systematic review found that physical activity is associated with survival benefits in breast cancer. 26 There were three exercise trials; two small single-arm prospective studies and one nonplacebo-controlled RCT. The issues for this group were similar to those of the yoga group; namely, potential for placebo effect, small sample size and the self-referred nature of participants.
The interventions were varied, accounting in part for the heteroge- In contrast, the intervention in the Nyrop et al.'s study 28 was a selfdirected, 6-week walking program designed to maximize feasibility and did not produce significant benefit. The Denysschen et al.'s study 29 protocol, an 8-week home-based program of prescribed resistance and aerobic exercises which yielded some positive results, lays between these extremes of efficacy and feasibility.
Acupuncture
Acupuncture is of growing interest among cancer centers, 30 and studies have demonstrated short-term analgesic effects in certain non-AIMSS musculoskeletal syndromes. 31 The mechanism is not clear, but may involve mediation of endogenous analgesic and inflammatory pathways. 32 The four acupuncture trials produced the most heterogeneous results. Only the Crew et al.'s trial 31 found true acupuncture to be more effective than sham; Bao et al. 33 and Oh et al. 34 found no difference between the two. Mao et al. 30 included an additional, waitlist control arm and found that true and sham acupuncture were both significantly better than waitlist control, but no different from each other.
This heterogeneity may partially be due to the differences between 
Omega-3 fatty acids
Several studies have suggested that omega-3 fatty acids may be effective in reducing pain in rheumatoid arthritis and back pain. 35 There was one placebo-controlled RCT of this intervention with 262 evaluable participants. 35 It did not show any difference between omega-3 fatty acid and placebo, but the placebo effect was larger than expected, with both arms exhibiting sustained improvements. The researchers hypothesized that this may be due to the natural history of AIMSS, with symptoms improving irrespective of the intervention, although it is also worth noting that 20% of participants were lost to follow-up, also potentially biasing the results.
The remaining studies were of miscellaneous interventions and were all small and uncontrolled.
Prednisolone
Corticosteroids have many significant side effects limiting their use in AIMSS. However, one single-arm study of 27 patients examined the safety and efficacy of a short-course of very low-dose prednisolone. 36 It found this intervention to be safe and beneficial in the short term, but only included follow-up measurement up to 2 months. It also used a protocol-specific, unvalidated questionnaire to measure outcomes.
Complementary regime
One single-arm trial studied a specific complementary medicine regime involving sodium selenite, plant enzymes (bromelaine and papain) and lens culinaris lectin. 37 The researchers hypothesized that antiestrogens cause arthralgia by thinning mucosal linings, and specifically included lens culinaris lectin because of its purported action on mucosal surfaces. It included 129 patients, some of whom were on antiestrogens other than AIs. Again, an unvalidated self-assessment score was used to measure the outcome. The trial found significant benefit with the regime and a follow-up RCT has been planned.
Duloxetine
One uncontrolled pilot study of 29 participants examined duloxetine, a serotonin-norepinephrine reuptake inhibitor known to be effective in certain chronic pain states including osteoarthritis and fibromyalgia. 38 It yielded positive results. The majority of the study cohort had already switched from one AI to another due to intolerable AIMSS. The researchers thus suggested that duloxetine may have a particularly pronounced effect in patients with more severe symptoms, although
this cannot be concluded with certainty from the very small sample size.
Glucosamine-sulfate + chondroitin-sulfate
One uncontrolled trial of 39 participants examined glucosaminesulfate combined with chondroitin-sulfate. 39 These substances are found in healthy cartilage and may have a role in reducing symptoms in a subgroup of osteoarthritis patients. 39 More than 36.9% of participants reported benefit, thus justifying progression to a larger trial according to the OMERACT-OARSI criteria cited by the study. However, 26.4% of patients were lost from enrollment to evaluation.
Immunologic therapy: thymosin [alpha]1
There is some evidence that disturbance of the balance of immune cytokines may contribute to AIMSS. 40 One uncontrolled pilot study of 16 participants found benefit from thymosin [alpha]1, a hormone produced by the thymus which can increase the immune function of cells. 40 
Kampo medicine
One case study found that a combination of Juzentaihoto followed by aconitine root, elements of traditional Japanese Kampo medicine, was followed by an improvement in arthralgia in a 55-year-old woman. 41 
Abstracts
In addition to the above published trials, there were nine studies available only in abstract form. There were two abstracts hydroxychloroquine, 45 testosterone undecanoate, 46 Iyengar yoga, 47 diuretic therapy, 48 switch of AI 49 and Tai Chi. 50 The trials and their interventions are listed only in Table 3 , as the remaining details could not be conclusively identified from the abstracts alone.
DISCUSSION
AIMSS is clinically important and many trials have undertaken to determine how to treat it, but the existing evidence contains numerous methodological problems. The largest contributor to risk of bias was the lack of control in the majority of trials. Furthermore, processes used for randomization, allocation concealment, blinding, outcome reporting and compliance measurement should be clearly documented and meet Cochrane Collaboration standards. Protocols should be registered pre-data collection to ensure transparent reporting of outcomes. Larger sample sizes are required, as many studies were not powered for efficacy and no trial had more than 260 participants.
In terms of intervention design, researchers should consider the duration of interventions and the use of follow-up measurement.
AIMSS is a chronic syndrome, with symptoms tending to peak after 6 months. 48 The median intervention duration was 2 months, with only four trials including follow-up outcome measurement. 30, 33, 34, 36 In designing active interventions such as yoga and exercise, researchers should consider the capabilities of the post-menopausal breast cancer population for their findings to be applicable.
The heterogeneity of outcome measures across trials meant that a meta-analysis was not feasible. Several trials used tools validated in settings other than AIMSS to measure pain severity and impact on function, the most commonly used being the BPI and the HAQ. The BPI is validated in cancer populations but not AIMSS specifically, 51 while the HAQ was originally developed for rheumatoid arthritis but has been incorporated in other settings. 52 Such differences in outcome measures may impact results, with Bao et al. 33 suggesting that the positive results attained by the Crew acupuncture trial 31 may relate to the BPI being more sensitive than the HAQ as used by Bao et al.
Castel et al. 53 have summarized the limitations of other commonly used survey instruments. A few trials did not employ even these and used unvalidated, protocol-specific questionnaires instead to measure outcomes, 36, 37 making it difficult to interpret the results in the context of the literature. Since the trials in this review, Castel et al. 53 One qualitative trial explored nonphysical themes often dismissed as placebo effect such as camaraderie and empowerment and suggested that they were integral to the positive effect of yoga. 23 Further qualitative trials to explore such factors may be valuable.
Further research into the mechanism of AIMSS and its potential treatment targets will be key to developing effective interventions. Among the interventions in this review, we believe that exercise most deserves further investigation, as supported by its association with improved survival in breast cancer and its proven benefit in osteoarthritis. Researchers have developed a 3-year RCT exercise protocol in colon cancer, with supervised sessions, behavioral support and health education for the intervention group and health education only for the control. 55 A 1-year feasibility report has so far been successful. 56 This controlled design, uniquely combining structured activity and motivational support, may provide the basis for a similar protocol in AIMSS.
Limitations of this review
The search strategy in this review may not have been exhaustive. First, it did not systematically look for trials in the reference lists of other articles, or in the gray literature. Furthermore, the initial search strategy which yielded over a thousand results relied heavily on manual filtering for refinement, and the search, inclusion and data extraction processes were all completed by one person. These two factors possibly increased the potential for inaccuracies.
CONCLUSIONS
Overall, although trends have emerged in the research supporting several interventions for AIMSS, no definitive evidence could be estab- 
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